HK1212683A1 - 多个激酶途径抑制剂 - Google Patents

多个激酶途径抑制剂 Download PDF

Info

Publication number
HK1212683A1
HK1212683A1 HK16100505.0A HK16100505A HK1212683A1 HK 1212683 A1 HK1212683 A1 HK 1212683A1 HK 16100505 A HK16100505 A HK 16100505A HK 1212683 A1 HK1212683 A1 HK 1212683A1
Authority
HK
Hong Kong
Prior art keywords
pathway inhibitors
kinase pathway
multiple kinase
kinase
inhibitors
Prior art date
Application number
HK16100505.0A
Other languages
English (en)
Chinese (zh)
Inventor
Qingping Zeng
Mary Faris
Alexis MOLLARD
Steven L. Warner
Gary A. Flynn
Original Assignee
Mannkind Corporation
Tolero Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corporation, Tolero Pharmaceuticals, Inc. filed Critical Mannkind Corporation
Publication of HK1212683A1 publication Critical patent/HK1212683A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16100505.0A 2012-09-26 2013-09-25 多个激酶途径抑制剂 HK1212683A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261706084P 2012-09-26 2012-09-26
US61/706,084 2012-09-26
US201361757331P 2013-01-28 2013-01-28
US61/757,331 2013-01-28
US201361785992P 2013-03-14 2013-03-14
US61/785,992 2013-03-14
PCT/US2013/061548 WO2014052365A1 (en) 2012-09-26 2013-09-25 Multiple kinase pathway inhibitors

Publications (1)

Publication Number Publication Date
HK1212683A1 true HK1212683A1 (zh) 2016-06-17

Family

ID=50388917

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100505.0A HK1212683A1 (zh) 2012-09-26 2013-09-25 多个激酶途径抑制剂

Country Status (8)

Country Link
US (2) US9493454B2 (enExample)
EP (1) EP2900668A4 (enExample)
JP (1) JP2015532281A (enExample)
CN (1) CN104812756A (enExample)
AU (1) AU2013323736A1 (enExample)
CA (1) CA2886275A1 (enExample)
HK (1) HK1212683A1 (enExample)
WO (1) WO2014052365A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3409278B8 (en) 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
AU2013323736A1 (en) * 2012-09-26 2015-04-09 Mannkind Corporation Multiple kinase pathway inhibitors
US10202356B2 (en) 2013-03-14 2019-02-12 Tolero Pharmaceuticals, Inc. JAK2 and ALK2 inhibitors and methods for their use
CN104418853B (zh) * 2013-08-28 2016-09-07 北大方正集团有限公司 取代的萘啶-2-酮化合物、制备方法、用途及药物组合物
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
WO2016161248A1 (en) * 2015-04-02 2016-10-06 Tolero Pharmaceuticals, Inc. Targeting pim kinases in combination with btk inhibition
EP4086264B1 (en) 2015-05-18 2023-10-25 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
CA2993659A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CN110382495B (zh) * 2016-12-16 2022-04-05 基石药业（苏州）有限公司 Cdk4/6抑制剂
CN108264511B (zh) * 2017-01-03 2021-04-13 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和其在医药上的用途
WO2018213219A1 (en) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
CA3096984A1 (en) 2018-04-05 2019-10-10 Sumitomo Dainippon Pharma Oncology, Inc. Axl kinase inhibitors and use of the same
US20210113562A1 (en) 2018-04-13 2021-04-22 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
CA3119807A1 (en) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2022510410A (ja) * 2018-12-07 2022-01-26 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 去勢抵抗性および去勢感受性前立腺がんを処置するための方法
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CN117430597A (zh) * 2022-07-14 2024-01-23 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
KR20010023089A (ko) * 1997-08-20 2001-03-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 단백질 티로신 키나제 및 세포주기 키나제 매개의 세포증식 억제용 나프티리디논
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
CA2542105C (en) 2003-10-08 2011-08-02 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2009537520A (ja) 2006-05-15 2009-10-29 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｆｇｆ受容体キナーゼ阻害剤のための組成物および方法
US8604031B2 (en) 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
AU2013323736A1 (en) * 2012-09-26 2015-04-09 Mannkind Corporation Multiple kinase pathway inhibitors

Also Published As

Publication number Publication date
AU2013323736A8 (en) 2015-04-30
US20170107215A1 (en) 2017-04-20
AU2013323736A1 (en) 2015-04-09
WO2014052365A1 (en) 2014-04-03
CN104812756A (zh) 2015-07-29
US9493454B2 (en) 2016-11-15
US9714247B2 (en) 2017-07-25
CA2886275A1 (en) 2014-04-03
EP2900668A4 (en) 2016-04-20
US20150266870A1 (en) 2015-09-24
JP2015532281A (ja) 2015-11-09
EP2900668A1 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
HK1212683A1 (zh) 多个激酶途径抑制剂
HK1202377A1 (en) Modulating certain tyrosine kinases
ZA201405140B (en) Disubstituted benzothienyl-pyrolotriazines and their use as fgfr kinase inhibitors
IL238571A0 (en) Broton tyrosine kinase inhibitors, preparations containing them and their uses
WO2016123054A3 (en) Kinase drug combinations and methods of use thereof
EP3060173A4 (en) Methods and systems for heart valve therapy
WO2012158843A3 (en) Kinase inhibitors
ZA201406273B (en) Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
EP3035800A4 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
SI2857404T1 (sl) Imidazo(1,2-b)piridazin derivati kot kinazni inhibitorji
PT2955185T (pt) Inibidores da atividade de cinase de pirazole substituído policíclico e sua utilização
EP2833889A4 (en) PROTEIN KINASE C HEMMER AND USES THEREOF
EP2683243A4 (en) PI3 KINASE INHIBITORS AND USES THEREOF
HRP20181294T1 (hr) Pirimidinilni inhibitori tirozinske kinaze
ZA201409256B (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
IL235418A0 (en) Biologically active projectiles, systems, and methods
EP2749777A4 (en) HYDRAULIC CIRCUIT, AND COMBINED VALVE USED IN THIS HYDRAULIC CIRCUIT
ZA201406777B (en) 3,5-diaminopyrazole kinase inhibitors
EP2870158A4 (en) PROTEIN KINASE INHIBITORS
EP3113776A4 (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
EP2855484A4 (en) PROTEIN KINASE INHIBITORS
EP3068389A4 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP2968995A4 (en) INHIBITORS OF LRRK2 KINASE ACTIVITY
EP3068378A4 (en) Random copolymer therapeutic agent carriers and assemblies thereof
CA142766S (en) Shelving unit